PROJECT IN DETAIL

The number of chronic diseases caused by adverse immune reactions is continuously increasing.
To date, this group of diseases affects over 10% of the global population. In addition to the high burden on the patients (chronicity, organ failure, early death, reduced quality of life), this results in great direct and indirect costs for society (EU: >100 billion €/year direct health care costs).

While symptoms can be treated, there is currently no cure.
Therapies have limited efficacy. Many times, the disturbed immune balance cannot be restored sustainably.
The consortium behind the “geneTIGA” project is addressing this problem using the example of IgA nephropathy (IgAN), the most common immunological kidney disease (glomerulonephritis), which is also one of the most common causes of kidney failure.

VISION & MISSION
VISION & MISSION

VISION & MISSION

Our ambitious goal is to develop a safe and efficient cell therapy based on genome-edited T cells with redirected specificity to sustainably combat IgA nephropathy (IgAN)
OBJECTIVES
OBJECTIVES

OBJECTIVES

Within the funding period geneTIGA aims to: identify specific Chimeric Antigen Receptor (CAR) and transgenic T Cell Receptor (tgTCR) candidates for redirected T cell mediated selective targeting
ORGANIZATION
ORGANIZATION

ORGANIZATION

The final goal of geneTIGA consortium is to create a T cell therapy against IgA-associated diseases using genome editing which will serve as a blueprint to expand the potential of cell-based gene therapies

Start

1 July 2022

Duration

48 Months

Funding

€ 5.7 Mio

Team

11 Partners

Latest News and Announcements